Global Blood Therapeutics Inc.
GBT
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.49B
Close$
$79.37
15.9% upside
Current Fair Value
15.9% upsideUndervalued by 15.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.49 Billion |
|---|---|
| Enterprise Value | $4.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.82 |
| Beta | 0.46 |
| Outstanding Shares | 65,594,792 |
Return
| Return on Equity | -275.75% |
|---|---|
| Return on Assets | -37.50% |
| Return on Invested Capital | -38.26% |
Valuation & Multiples
| P/E Ratio | -14.21 |
|---|---|
| PEG | -76.79 |
| Price to Sales | 22.83 |
| Price to Book Ratio | 68.49 |
| Enterprise Value to Revenue | 20.82 |
| Enterprise Value to EBIT | -16.44 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 5.56 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Global Blood Therapeutics Inc.
CEO: Ted Love